Document Type
Plan B - Open Access
Award Date
2022
Degree Name
Master of Science (MS)
Department
Biology and Microbiology
First Advisor
Greg Heiberger
Abstract
The development of immune-checkpoint-inhibitors (ICIs) has led to promising advancements in the treatment of patients with cancers, leading with the use of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) as a negative regulator of T cell activation in the mid-1990s. With the discovery of two ligands for program cell death protein-1 (PD-1) and promising checkpoint blockades in 2010, this sparked a cascade of hallmark immunotherapy drug patents, focusing on the mechanism of anti PD-1 and anti PD-L1 antibody inhibitors. Since then, chimeric antigen receptor (CAR)-engineered T (CAR-T) cells have emerged into the immuno-oncologic scene for treatment of hematological malignancies. These genetically modified T-cells focus on the destruction cancer cells without the need of chemotherapy.
Number of Pages
23
Publisher
South Dakota State University
Rights
© 2022 Brian Stahl
Recommended Citation
Stahl, Brian, "Chimeric Antigen Receptor T-Cell Therapy in Cancer" (2022). Biology and Microbiology Graduate Students Plan B Research Projects. 39.
https://openprairie.sdstate.edu/biomicro_plan-b/39